CoChat

Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis

Masson, Walter, Lavalle-Cobo, Augusto, Lobo, Martín, Masson, Gerardo, Molinero, Graciela · 2021 · European Journal of Preventive Cardiology

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Aims: To evaluate the effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) on major cardiovascular events (MACE) in metformin-naïve patients with type 2 diabetes (T2D). Methods and results: A meta-analysis was performed of randomized controlled clinical trials of GLP-1RAs and SGLT-2 inhibitors on T2D populations, after searching the PubMed/MEDLINE, Embase, and Cochrane Controlled Trials databases. The primary endpoint was MACE. The secondary endpoint, explored in the subgroup of SGLT-2 inhibitors studies, was cardiovascular death or hospitalization for heart failure. A random-effects meta-analysis model was applied. Six eligible trials (three studies of SGLT-2 inhibitors and three trials of GLP-1RAs), including 13 049 patients, were identified and considered eligible for the analyses. The new antidiabetic drugs were associated with a significant reduction in MACE [odds ratio (OR): 0.80, 95% confidence interval: 0.70–0.93; I2: 53%]. The subgroup analysis showed the following findings: GLP-1RAs group, OR: 0.77 (95% confidence interval 0.67–0.88); SGLT-2 inhibitors, OR: 0.85 (95% confidence interval 0.63–1.15). SGLT-2 inhibitors were associated with a significant reduction in hospitalization for heart failure or cardiovascular mortality incidence (OR: 0.67, 95% confidence interval: 0.47–0.95; I2: 78%). Conclusion: In this meta-analysis, new antidiabetic drugs reduced the incidence of MACE in metformin-naïve T2D patients. The beneficial effect was especially observed in the GLP-1RAs subgroup. The use of SGLT-2 inhibitors was associated with a reduction in cardiovascular death or hospitalization for heart failure. These results support the fact that metformin would not be indispensable to obtain positive cardiovascular effects when new antidiabetic drugs are administered.

Overview

Integrity signals

Registry

Crossref · 10.1093/eurjpc/zwaa074

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 28 references

Research works printed but not linked: 2

  1. 2010, Viechtbauer W. Conducting meta-analyses in R with the metaphor package, J Stat Softw, 36, 1
  2. Hüttner, 2017, EMPA-REG OUTCOME: empagliflozin (EMPA) reduced the risk of cardiovascular (CV) outcomes and mortality irrespective of metformin (MET) use at baseline, Diabetologia, 60(Suppl1, S1

Cited by

See all 37

Metadata

Authors
Masson, W., Lavalle-Cobo, A., Lobo, M., Masson, G., & Molinero, G.
Affiliations
  • Hospital Italiano de Buenos Aires (AR)
  • Council of Epidemiology and Cardiovascular Prevention, Argentine Society of Cardiology, Azcuenaga 980, Buenos Aires C1115AAD, Argentina
Corresponding author
Masson, Walter
Venue
European Journal of Preventive Cardiology
Published
2020-09-30
Volume
28
Issue
1
Pages
69-75
ISSN
  • 2047-4873 (ISSN-L)
  • 2047-4881
OpenAlex
W3122732357
Cited by
37
References
28
Citations by year
2026: 1 · 2025: 4 · 2024: 12 · 2023: 2 · 2022: 7 · 2021: 11
FWCI
0.77
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Preventive Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
SGLT2 inhibitors, GLP-1 receptor agonists, type 2 diabetes, major adverse cardiovascular events, cardiovascular mortality, heart failure hospitalization, antidiabetic drugs, cardiovascular safety
MeSH terms
Glucagon-Like Peptide-1 Receptor, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Heart Failure, Humans, Hypoglycemic Agents, Metformin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis. https://app.cochat.ai/papers/10.1093/eurjpc/zwaa074
The paper
Masson, W., Lavalle-Cobo, A., Lobo, M., Masson, G., & Molinero, G. (2021). Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis. European Journal of Preventive Cardiology. https://doi.org/10.1093/eurjpc/zwaa074

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.